ANDA 83123, held by Watson Laboratories. Brompheniramine Maleate.
As of Nov 21, 2026, ANDA 83123 (Brompheniramine Maleate), held by Watson Laboratories, was first approved by FDA on Nov 15, 1976, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 15, 1976 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Brompheniramine Maleate4MG · tablet;oral | Brompheniramine Maleate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters